Drug name - Vibativ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6635618 | CUMBERLAND PHARMS | Glycopeptide phosphonate derivatives |
Sep, 2023
(11 months from now) | |
| US7531623 | CUMBERLAND PHARMS | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(4 years from now) | |
| CN1441680A | CUMBERLAND PHARMS | Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin |
May, 2021
(1 year, 4 months ago) | |
| CN1432023A | CUMBERLAND PHARMS | Reductive Alkylation Process |
May, 2021
(1 year, 4 months ago) | |
| CN100532392C | CUMBERLAND PHARMS | Reductive Alkylation Method |
May, 2021
(1 year, 4 months ago) | |
| CN1437611A | CUMBERLAND PHARMS | Glycopeptide Phosphonic Acid Salt Derivatives |
May, 2021
(1 year, 4 months ago) | |
| CN1223378C | CUMBERLAND PHARMS | Pharmaceutical Compositions Containing A Glycopeptide Antibiotic And A Cyclodextrin |
May, 2021
(1 year, 4 months ago) | |
| CN100469788C | CUMBERLAND PHARMS | Glycopeptide Phosphonic Acid Salt Derivatives |
May, 2021
(1 year, 4 months ago) | |
| CN100417661C | CUMBERLAND PHARMS | Hydrochloride Of Glycopeptide Phosphonate Derivatives |
Oct, 2024
(2 years from now) | |
| CN1871253A | CUMBERLAND PHARMS | Hydrochloride Of Glycopeptide Phosphonate Derivatives |
Oct, 2024
(2 years from now) | |
| IN200201986P4 | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2021
(1 year, 4 months ago) | |
| IN206947B | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2021
(1 year, 4 months ago) | |
| EP1276759B1 | CUMBERLAND PHARMS | Reductive Alkylation Process On Glycopeptides |
Apr, 2021
(1 year, 4 months ago) | |
| EP1278549B1 | CUMBERLAND PHARMS | Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic |
Apr, 2021
(1 year, 4 months ago) | |
| EP1276759A2 | CUMBERLAND PHARMS | Reductive Alkylation Process On Glycopeptides |
Apr, 2021
(1 year, 4 months ago) | |
| EP1278549A2 | CUMBERLAND PHARMS | Composition Containing A Cyclodextrin And A Glycopeptide Antibiotic |
Apr, 2021
(1 year, 4 months ago) | |
| EP1292611A2 | CUMBERLAND PHARMS | Glycopeptide Carboxy-Saccharide Derivatives |
May, 2021
(1 year, 4 months ago) | |
| EP1292611B1 | CUMBERLAND PHARMS | Glycopeptide Carboxy-Saccharide Derivatives |
May, 2021
(1 year, 4 months ago) | |
| EP1678201B1 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP2495251B1 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP2495251A1 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP1678201A2 | CUMBERLAND PHARMS | Hydrochloride Salts Of A Glycopeptide Phosphonate Derivative |
Oct, 2024
(2 years from now) | |
| EP1292612A2 | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2026
(3 years from now) | |
| EP1292612B1 | CUMBERLAND PHARMS | Glycopeptide Phosphonate Derivatives |
May, 2026
(3 years from now) | |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 250MG BASE/VIAL | POWDER;INTRAVENOUS | Discontinued |
| EQ 750MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.